prostaglandin E receptor 4 pseudogene 3Genealiases: []
Q-omics provides the consensus-scored PTGER4P3 profile across patient tissues and cancer cell-line models. PTGER4P3 expression is associated with patient survival in 6 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, PTGER4P3 is differentially expressed in 1, with the highest sampling consensus in THCA. Additionally, PTGER4P3 RNA expression shows 6,346 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight LUAD, THCA, and STAD as cancer lineages where PTGER4P3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PTGER4P3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PTGER4P3 survival associations across molecular data types. PTGER4P3 RNA expression shows survival associations in the most cancer types (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PTGER4P3 RNA expression–survival associations across cancer types. High PTGER4P3 expression shows unfavorable associations in LUAD, ACC, DLBC and UCEC, but favorable associations in SKCM and LGG. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for PTGER4P3 RNA expression.
This table summarizes PTGER4P3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for PTGER4P3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PTGER4P3 shows higher tumor expression in THCA. The THCA box plot shows higher PTGER4P3 RNA expression in tumor versus normal tissue (log2 FC = +0.036, t-test p = .044).
This table shows molecular features associated with PTGER4P3 in patient tissues and cancer cell lines. In patient samples, PTGER4P3 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
